Cellectar plans Phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 (NASDAQ:CLRB)

Cellectar Biosciences (CLRB) Q1 2026 earnings call: iopofosine 12-month CLOVER data, $140M financing, Phase III & FDA timeline to 2027.